Peptide Regulation in Australia: The TGA's Role, Explained
Updated 2026-09-03
How the Therapeutic Goods Administration classifies peptides, why scheduling and personal importation rules matter, and where to check current status.
The short answer
In Australia, the Therapeutic Goods Administration (TGA) regulates peptides through two overlapping mechanisms: registration or listing of a specific therapeutic good under the Therapeutic Goods Act 1989, and scheduling of the underlying substance under the Poisons Standard (the Standard for the Uniform Scheduling of Medicines and Poisons, commonly called the SUSMP). Most peptides discussed in research, bodybuilding, or general wellness contexts have neither a registered therapeutic good nor unrestricted scheduling, which places them outside lawful general supply even where the substance itself is not a prohibited narcotic.
Why this comes up
Australian readers often encounter peptides through overseas online sellers, gym or clinic recommendations, or international research discussion, and assume that because a substance is not a controlled drug in the traditional sense, it must be broadly legal to obtain. The TGA's dual system of product registration and substance scheduling means a peptide can simultaneously be unapproved as a therapeutic good and restricted or prescription-only under the Poisons Standard, both of which affect legal access independently of each other.
Current regulatory status
The Therapeutic Goods Act 1989 gives the TGA authority to evaluate and register medicines, including peptide-based products, before they can be lawfully supplied in Australia for a therapeutic purpose. Peptide medicines with an established indication, such as GLP-1 receptor agonist products approved for chronic weight management or type 2 diabetes, are examples of peptides that have gone through TGA registration and carry an approved label and indication. Separately, the Poisons Standard schedules substances by risk and control level; many peptide-related substances used in growth-hormone-adjacent or performance contexts are scheduled as prescription-only (Schedule 4) or more tightly controlled, meaning lawful supply generally requires a prescription from an Australian-registered medical practitioner and dispensing through an appropriately licensed pharmacy, independent of whether a specific branded product is TGA-registered.
Australia also operates a personal importation scheme that, under specific conditions, allows an individual to import a limited quantity of certain unapproved therapeutic goods for their own use, generally intended to cover cases where a person has an ongoing prescription-based need or a practitioner's involvement rather than functioning as an open channel for any substance a buyer finds online. The TGA has taken compliance and enforcement action over the years connected to peptide products supplied outside these frameworks, including against clinics and compounders found to be advertising or supplying unapproved and unscheduled-inconsistent peptide products; this article does not itemize specific enforcement cases, since those are best checked directly against the TGA's current public compliance actions.
Common misconceptions
If a peptide is not illegal to possess, it is legal to buy and use freely. Poisons Standard scheduling can require a prescription for lawful supply even when simple possession is not itself a separate criminal offense, so "not illegal to possess" and "lawful to obtain and use" are not the same status.
The personal importation scheme lets anyone import any peptide for themselves. The scheme has defined conditions, quantity limits, and exclusions depending on the substance and its schedule; it is not a general workaround for substances that are prescription-only or otherwise restricted.
A compounding pharmacist can prepare any peptide a prescriber requests. Australian compounding practice operates under Pharmacy Board of Australia standards and TGA compounding guidance, both of which restrict which substances and preparations are appropriate for compounding, particularly where a substance's safety and quality data are limited.
What this means for you
An Australian reader considering a peptide should check both whether a TGA-registered therapeutic good exists for the intended use and how the underlying substance is scheduled under the Poisons Standard, since either factor alone can determine whether a prescription and a licensed pharmacy are legally required. Readers considering personal importation should review the TGA's specific conditions for that scheme before assuming a purchase is covered, and should treat a seller's own description of "personal use legality" as unverified until checked against TGA guidance directly.
Questions to ask before considering a peptide product in Australia
- Is there a TGA-registered therapeutic good for this specific peptide and intended use, and separately, how is the substance itself scheduled under the Poisons Standard?
- If personal importation is being considered, do the quantity and eligibility conditions of the TGA's scheme actually cover this substance and this situation?
- Is the prescriber and pharmacy involved appropriately registered, and can that be verified independently of the seller's own claims?
- Has the TGA published any compliance notice or public warning connected to this substance, this clinic, or this compounder?
FAQ
Does the TGA approve peptides for general sale in Australia? The Therapeutic Goods Administration (TGA) evaluates and registers therapeutic goods under the Therapeutic Goods Act 1989, and separately schedules substances under the Poisons Standard. A peptide with no TGA registration is not an approved therapeutic good, even if it is discussed widely online or sold from overseas.
What does it mean for a peptide to be a "scheduled" substance in Australia? Scheduling under the Poisons Standard (SUSMP) sets the level of control on how a substance can be supplied, for example prescription-only versus unscheduled. A peptide's schedule status is a separate question from whether it has a registered therapeutic good using it, and both affect legal access.
Can an individual legally import a peptide for personal use in Australia? Australia has a personal importation scheme that allows limited quantities of certain unapproved therapeutic goods for an individual's own use under specific conditions, but it does not apply to every substance or every schedule category, and it is not the same as a blanket allowance to buy any peptide from overseas.
Where can someone verify a specific peptide's current TGA status? The TGA's own website, including its therapeutic goods register and Poisons Standard scheduling decisions, is the primary reference, and a registered Australian pharmacist or medical practitioner can advise on a specific substance.
Sources
- Therapeutic Goods Administration, homepage -- https://www.tga.gov.au/
- Therapeutic Goods Administration, "How We Regulate" -- https://www.tga.gov.au/how-we-regulate
This distinction between product registration and substance scheduling is also why two peptides that seem similar in how they are marketed online can sit in very different legal positions in Australia: one might be part of a registered, prescribable product with an approved indication, while a closely related compound with no registered product and an unscheduled or insufficiently reviewed status sits entirely outside the same protections and oversight.
Disclaimer
This content is for general education only and is not medical advice, diagnosis, or treatment. Peptide Briefs does not sell peptides and does not recommend any specific product, dose, or protocol. These statements have not been evaluated by the Food and Drug Administration. Always talk with a licensed healthcare provider before starting, stopping, or changing any therapy.